FMP
Trillium Therapeutics Inc.
TRIL
NASDAQ
Inactive Equity
Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. Its product candidates also include TTI-622 that is in Phase I clinical trial of immunoglobulin G4 SIRPaFc protein; and TTI-10001, a small molecule stimulator of interferon genes agonist that senses cytosolic DNA for promoting tumor immunity, which is in the discovery Phase. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 is headquartered in Mississauga, Canada.
18.44 USD
0 (0%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Dr. Jan Skvarka
sector
Healthcare
industry
Biotechnology
exchange
NASDAQ
Description
Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. Its product candidates also include TTI-622 that is in Phase I clinical trial of immunoglobulin G4 SIRPaFc protein; and TTI-10001, a small molecule stimulator of interferon genes agonist that senses cytosolic DNA for promoting tumor immunity, which is in the discovery Phase. The company was...
CIK
0001616212
ISIN
CA89620X5064
CUSIP
89620X506
Address
2488 Dunwin Dr
Phone
14165950627
Country
CA
Employee
33
IPO Date
Jan 11, 2005
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
TRIL Financial Summary
CIK
0001616212
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
89620X506
ISIN
CA89620X5064
Country
CA
Price
18.44
Beta
1.9
Volume Avg.
1.98M
Market Cap
0
Shares
-
52-Week
17.83-18.49
DCF
21.39
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
0
P/B
-
Website
http://trilliumtherapeutics.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest TRIL News
It looks like there's no news available.
